News / Taiwan / economic_daily
PharmaEssentia September Revenue Doubles, Hits Record High on Strong Drug Demand
Health Technology · Biotechnology · economic_daily · 2026-10-05
6446
PharmaEssentia reported a 100% year-over-year revenue surge for September, driven by the global expansion of its rare blood cancer treatment, Ropeg.
What Happened
Financial Performance: PharmaEssentia announced a record-breaking monthly revenue of NT$2.64 billion for September, marking a 100% increase compared to the same period last year. The company's cumulative revenue for the first three quarters reached NT$19.73 billion, representing an 83.5% year-over-year growth.
Growth Drivers: The company's core drug, Ropeg, has become a key growth driver following its approval for both Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Strong demand from major hospitals in the U.S. and Japan has significantly bolstered the company's financial results.
Global Expansion: PharmaEssentia is actively expanding its international footprint, with regulatory reviews underway in South Korea and China, and plans to initiate drug approval applications in Australia. The company continues to solidify its leadership in MPN treatment through ongoing clinical trials and strategic market penetration.
Industry Impact: The company's achievements have been recognized by high-level government officials as a milestone for Taiwan's biotechnology sector. PharmaEssentia is viewed as a successful model for domestic firms aiming to integrate into the global pharmaceutical market.